Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April May June July August September October November December
Previous Archive
30 August 2022 | Story André Damons | Photo André Damons
UFS Nuclear Medicine
The team of doctors in the Department of Nuclear Medicine behind the success story are, from the left (standing): Dr Osayande Evbuomwan, nuclear medicine specialist and Senior Lecturer; Dr Gerrit Engelbrecht, Clinical Head of the Department of Nuclear Medicine at the UFS; and Dr Walter Endres, nuclear medicine registrar. In front is Dr Tebatso Tebeila, nuclear medicine registrar.
The University of the Free State (UFS) Department of Nuclear Medicine is proud to announce the successful treatment outcome of a patient with metastatic castrate-resistant prostate cancer (MCRPC) – an advanced stage of prostate cancer – by using Lutetium 177 PSMA (Lu-177 PSMA) therapy. This was initially a case of advanced stage prostate cancer, which had failed first-line chemotherapy, leaving little or no other treatment options.

This is a proud and happy moment for the department and the UFS, which started this treatment just over a year ago. The university and the Free State province are now joining other South African medical universities, such as the University of Pretoria, and other provinces in using this method to treat MCRPC patients. Lutetium 177 PSMA (Lu-177 PSMA) therapy is used on MCRPC patients who are not eligible for chemotherapy or have failed first- or second-line chemotherapy.

Dr Gerrit Engelbrecht, Clinical Head of the Department of Nuclear Medicine at the UFS, says the department is proud to be able to offer this treatment option to some of these patients. “It is a big win for the Free State and our oncology patients to be able to offer these expert services.” The UFS and Universitas Academic Hospital have now been able to join up with other academic institutions and hospitals in other provinces to offer these services. So far, three patients have been offered this therapeutic option, with the third patient currently undergoing his treatment.

Funds and equipment for proper treatment selection are needed

The expertise is no longer an issue for the UFS, as Dr Osayande Evbuomwan, nuclear medicine specialist and consultant, was trained and exposed to this therapy at the University of the Witwatersrand during his training as a nuclear medicine resident. Current registrars in the Department of Nuclear Medicine at the UFS are also being trained in the application of this treatment modality. However, proper patient selection is key in the management of these cases with Lu 177 PSMA. Without a PET/CT camera, it is challenging to appropriately select the patients who are most likely to respond to this therapy. This is an example of how PET/CT is crucial in the management and monitoring of oncology patients.

Both Drs Engelbrecht and Evbuomwan hope that the training of more registrars will increase their department’s capacity to treat more patients. They also hope that funds will be made available to acquire a much-needed PET/CT camera, which will greatly assist them in identifying the correct patients in need of this treatment. 

With the permission of the patient, the images above show the dramatic treatment response following Lu-177 PSMA therapy. The images on the left show widespread bone disease from the prostate cancer, including the skull. The images on the right show the dramatic response after completing four cycles of Lu 177 PSMA, with the normal excretion of the radiotracer seen in the liver, kidneys, and bladder.


Treatment puts the department, UFS, and hospital on the map

According to Dr Evbuomwan, the ability to administer this treatment puts the department, the UFS, and the hospital on the map, alongside other top universities within and outside the country. Says he: “It also creates an avenue for us to gather data for training, research purposes, and publications. We are now able to offer a promising, safe, and highly efficacious therapy for patients with MCRPC in the Free State. Some of these patients will no longer have to travel to other provinces to receive this treatment.”


“We are also well aware that not every patient will respond this way; however, proper patient selection is key in identifying responders – an area that is still being researched. We also do not know how long these patients will have their disease under control after the treatment. Nuclear medicine’s greatest cancer therapy success story is the treatment of well-differentiated thyroid cancer with radioactive iodine.” 

“After treatment, most of these patients remain cancer-free for a very long period of time, if not for life. With continuing research in the field of MCRPC radioligand therapy, we aim to improve the treatment modality, hopefully getting it to the success level of thyroid cancer therapy.”

 

News Archive

UFS acknowledge 53 for long service
2004-11-03

Long service awards for 35 years: Mrs. Christa du Plessis, Centre for Higher Education studies and Development, mnr. John Moorosi, Soil- and Crop- and Climate Sciences , prof. Frederick Fourie, rector, prof. Jopie Botha, Institute for Groundwater Studies, me. Susan Reineke, Plant Sciences, Dr. Sarie van Vuuren of Sociology and me. Aletta de Klerk, Kovsie Sport.

Fifty three personnel members received long service awards in the centenary year of the university for respectively 35 years of service and 25 years of service.

Prof. Frederick Fourie, Rector, said to the recipients of the long service awards: “In a year in which the writing of history of the UFS took a prominent place in the Centenary celebrations and in which one relived the past hundred years, the value we add to the university on a daily basis is clearly visible. Many personnel members contributed to make the UFS a valued institution and will proceed to do that in the spirit of 100+.”

He thanked and acknowledged personnel for the plus they add to each day’s work. “The students which enter the UFS each year, want to thank you for an university which on an innovative manner impacted their lives. “You helped to create the building blocks for their future,” he said.

Prof. J. F. Botha, Mr M.G. Botha, Ms A. De Klerk, Mr M.J. Doman, Prof. H.C. Janse van Rensburg and Ms S.M.C. Reinecke received awards for 35 years of service.

For 25 years of service at the university Prof. S.L. Barnard, Mr B. Botma, Dr H. J. Breytenbach, Dr M.W. Brussow, Mr N.L. Combrink, Ms A.J. Du Plessis, Ms C. Du Plessis, Prof. L. Goedhals, Mr M.E. Hlazo, Prof. B.B. Hoek, Dr S.J.E. Janse van Vuuren, Mr M. Kgasane, Ms A. Kgosi, Dr W.P. Konig, Dr P.A.L. Le Roux, Prof. N.J. Luwes, Dr N. Luyt, Ms S.E. November, Ms M. Mabaso, Ms M.K. Maruping, Prof. J.D. Marx, Mr J.P. Masedi, Mr G. Mokapane, Mr J. Mokapane, Ms M.L. Molosi, Ms M.M. Molwagale, Mr P.J. Moorosi, Ms C. Moroagae, Ms E. Moroale, Mr G.G. Mothokwane, Prof. M. Mulder, Prof. A.C. Otto, Ms H. Pelser, Ms E. Pelzer, Ms M.M. Pheko, Prof. E. Pretorius, Ms M.P. Richter, Ms E. Rouls, Prof. M.T. Seaman, Prof. R.B. Snowdowne, Prof. J.P. Strauss, Ms M.S. Tsolo, Prof. H.J. van der Linde, Dr S. van Vuuren, Prof. J.B. van Wyk, Dr J.M. van Zyl, Prof. T. Verschoor and Ms M.H.S. York received an long service award.

“Be assured of my appreciation for your loyalty and commitment to a university which is taking careful steps into a new century of its existence. If we do the right things right and with a sincere belief in our heavenly Father we will be able to build on the solid foundation laid by people like you,” he said.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept